OncoSec Medical (OTC:ONCS) said Friday that Patrick Cox, editor of Breakthrough Technology Alert and Technology Profits Confidential, thinks the company was "going to do well" with its new cancer drug.
Cox's comments were made in a recent interview with Streetwise Reports.
Cox, who also contributes to The Daily Reckoning, is a researcher, editor and contributor to various publications, who also
analyzes and speaks out on companies the he believes have potential for high returns to investors.
With regards to OncoSec, Cox said it is "an important company."
doesn't want to be thought of as a device company, but it has a patent
on the use of electroporation for the delivery of drugs," Cox said.
very small electrical charges, cell walls are opened up so that you can
deliver drugs. OncoSec is focused on a specific cancer drug right now.
think it's going to do well...what the company needs to do is
demonstrate efficacy, and I think it will do that. Then you're going to
see not only interest in the drug it is testing but also the application
of its device to a bunch of other drugs."
The full article can be viewed at http://www.thelifesciencesreport.com/pub/na/13495.
Medical is a biopharmaceutical company developing advanced-stage OMS
ElectroOncology therapies to treat solid tumors and metastatic disease.
The company said that treatment of various solid cancers using targeted
anti-cancer agents has demonstrated selective destruction of cancerous
cells while sparing healthy normal tissues during early and late stage
This week, the company issued a letter to its shareholders reviewing the key developments of the company so far in 2012.
a financial update, OncoSec said it recently raised $7.75 million
through a public offering to continue clinical development programs. The
offering was underwritten by Rodman & Renshaw, with Roth Capital
Partners acting as an advisor.
The company currently has over
$6.5 million in cash reserves to fund operations, which it said should
be sufficient to complete current studies.
OncoSec is executing
its clinical development plan based on its OMS ElectroImmunotherapy
platform for the treatment of rare and deadly skin cancers including
metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell
The company noted that it has initiated and enrolled
several patients in a phase II study for the treatment of metastatic
melanoma, called OMS-I100, and is expecting to report interim clinical
data before year end.
The company has also initiated and
enrolled several patients in a phase II study for the treatment of
Merkel cell carcinoma, called OMS-I110, and expects to report interim
clinical data before year end.
OncoSec said it is aiming to
initiate and begin enrolling patients in a phase II study for the
treatment of cutaneous T-cell lymphoma (CTCL), called OMS-I120, by
Since the acquisition of a clinical data set of over
400 patients, OncoSec said it has compiled, reviewed, and analyzed the
data and presented preliminary results from a phase IV European head and
neck cancer trial and phase I/II breast cancer trial.
preliminary data sets from the completed phase III recurrent head and
neck cancer studies carried out in the US are now being analyzed, and
the company said it intends to present the data at the 5th International
Head and Neck Cancer Conference taking place July 21-25.
corporate front, OncoSec said it is developing new applications of its
OMS ElectroOncology for treating solid tumors and metastatic disease,
with the goal of expanding market opportunities and establishing
additional patents to maintain its dominance in these areas.
company noted that its OMS ElectroImmunotherapy for the treatment of
metastatic melanoma and Merkel cell carcinoma was featured in Xconomy,
Medical Device & Diagnostic Industry, Manufacturing Chemist, and the
San Diego Business Journal.
OncoSec also said that its OMS
therapy was featured as a "revolutionary cancer treatment" for Merkel
cell carcinoma by a local NBC News affiliate in Seattle, Washington.